United Therapeutics Corporation (UTHR) Cut to Sell at BidaskClub

United Therapeutics Corporation (NASDAQ:UTHR) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday, July 31st.

A number of other equities research analysts also recently weighed in on the company. ValuEngine downgraded United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Jefferies Group LLC reissued a “sell” rating and set a $105.00 target price on shares of United Therapeutics Corporation in a research report on Friday, July 14th. Zacks Investment Research downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. UBS AG reissued a “sell” rating and set a $106.00 target price on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. Finally, Wedbush reissued an “outperform” rating and set a $213.00 target price (down from $229.00) on shares of United Therapeutics Corporation in a research report on Thursday, April 27th. Six analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $134.50.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) traded up 0.95% during mid-day trading on Monday, reaching $128.23. The company’s stock had a trading volume of 457,333 shares. United Therapeutics Corporation has a 12 month low of $110.90 and a 12 month high of $169.89. The stock has a market capitalization of $5.57 billion, a P/E ratio of 14.87 and a beta of 1.51. The company has a 50 day moving average price of $130.60 and a 200 day moving average price of $135.35.

United Therapeutics Corporation (NASDAQ:UTHR) last released its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of $3.61 by $4.86. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The firm had revenue of $444.60 million for the quarter, compared to analyst estimates of $391.53 million. During the same period last year, the business earned $4.42 earnings per share. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, equities research analysts anticipate that United Therapeutics Corporation will post $10.70 earnings per share for the current fiscal year.

United Therapeutics Corporation declared that its board has initiated a share repurchase plan on Thursday, April 27th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the biotechnology company to reacquire up to 4.6% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

COPYRIGHT VIOLATION NOTICE: “United Therapeutics Corporation (UTHR) Cut to Sell at BidaskClub” was reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.thestockobserver.com/2017/08/12/bidaskclub-downgrades-united-therapeutics-corporation-uthr-to-sell-updated.html.

In other news, Director Christopher Causey sold 590 shares of United Therapeutics Corporation stock in a transaction that occurred on Thursday, July 6th. The shares were sold at an average price of $132.61, for a total value of $78,239.90. Following the completion of the transaction, the director now owns 3,875 shares in the company, valued at $513,863.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard Giltner sold 3,490 shares of the business’s stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $131.12, for a total transaction of $457,608.80. The disclosure for this sale can be found here. Insiders sold 24,675 shares of company stock valued at $3,181,693 in the last quarter. 7.80% of the stock is currently owned by corporate insiders.

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. boosted its stake in shares of United Therapeutics Corporation by 4,222.8% in the first quarter. BlackRock Inc. now owns 4,741,985 shares of the biotechnology company’s stock valued at $641,969,000 after buying an additional 4,632,287 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of United Therapeutics Corporation by 144.0% in the second quarter. Wells Fargo & Company MN now owns 730,634 shares of the biotechnology company’s stock valued at $94,785,000 after buying an additional 431,210 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of United Therapeutics Corporation by 308.6% in the second quarter. JPMorgan Chase & Co. now owns 500,499 shares of the biotechnology company’s stock valued at $64,930,000 after buying an additional 378,002 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of United Therapeutics Corporation by 27.8% in the first quarter. AQR Capital Management LLC now owns 1,736,357 shares of the biotechnology company’s stock valued at $235,068,000 after buying an additional 377,395 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of United Therapeutics Corporation by 65.5% in the second quarter. Renaissance Technologies LLC now owns 837,600 shares of the biotechnology company’s stock valued at $108,662,000 after buying an additional 331,400 shares during the last quarter.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply